you are an Asterias stockholder and, at any time, you no longer wish to participate in householding and would prefer to receive
a separate joint proxy statement/prospectus, or if you are receiving multiple copies of this joint proxy statement/prospectus
and wish to receive only one, please call Advantage Proxy, the proxy solicitor for Asterias, toll-free at 877-870-8565 or international
at +206-870-8565 or write to Advantage Proxy at P.O. Box 13581, Des Moines, WA 98198. If you are an Asterias stockholder and hold
shares in street name, you may request a separate copy by calling Investor Relations at 510 456-3892, or by writing to Investor
Relations, Asterias Biotherapeutics, Inc. 6300 Dumbarton Circle, Fremont, California, 94555.
future annual or special meetings, BioTime shareholders and Asterias stockholders may request separate voting materials, or request
that BioTime or Asterias, respectively, send only one set of proxy materials by contacting Investor Relations at the above phone
number or address.
YOU CAN FIND MORE INFORMATION
and Asterias file annual, quarterly and special reports, proxy statements and other information with the SEC under the Exchange
Act. You may read and copy any of this information at the SEC’s Public Reference Room at 100 F Street, N.E., Room 1580,
Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the Public Reference Room. The SEC also
maintains an Internet website that contains reports, proxy and information statements, and other information regarding issuers,
including BioTime and Asterias, who file electronically with the SEC. The address of that site is www.sec.gov.
may also consult BioTime’s or Asterias’ website for more information concerning the Merger described in this joint
proxy statement/prospectus. BioTime’s website is www.biotimeinc.com. Asterias’ website is www.asteriasbiotherapeutics.com.
Information included on either website is not incorporated by reference into this joint proxy statement/prospectus. The information
contained on the websites of BioTime, Asterias and the SEC (except for the filings described below) is expressly not incorporated
by reference into this joint proxy statement/prospectus.
has filed with the SEC a Registration Statement of which this joint proxy statement/prospectus forms a part. The registration
statement registers the BioTime Common Shares to be issued to Asterias stockholders in connection with the Merger. The registration
statement, including the attached exhibits and schedules, contains additional relevant information about BioTime Common Shares.
The rules and regulations of the SEC allow BioTime and Asterias to omit certain information included in the registration statement
from this joint proxy statement/prospectus.
addition, the SEC allows BioTime and Asterias to disclose important information to you by referring you to other documents filed
separately with the SEC. This information is considered to be a part of this joint proxy statement/prospectus, except for any
information that is superseded by information included directly in this joint proxy statement/prospectus.
joint proxy statement/prospectus incorporates by reference the documents listed below that BioTime has previously filed or will
file with the SEC (other than information furnished pursuant to Item 2.02 or Item 7.01 of a Current Report on Form 8-K). They
contain important information about BioTime, its financial condition and other matters.
Report on Form 10-K for the fiscal year ended December 31, 2017.|
| || || |
Statement on Schedule 14A filed March 29, 2018.|
| || || |
Reports on Form 10-Q for the quarterly periods ended March 31, 2018, June 30, 2018 and
September 30, 2018.|
| || || |
Reports on Form 8-K dated September 18, 2018, October 5, 2018, November 8, 2018,
December 20, 2018 and January 4, 2019 (other than the portions of those documents
deemed to be furnished and not filed).
| || || |
description of BioTime Common Shares on Form 8-A (File No. 001-12830) filed with SEC
on October 26, 2009, as amended.|